MMSC 438 Verified Multiple Choice and
Conceptual Actual Frequently Tested Exam
Questions With Reviewed 100% Correct
Detailed Answers
Guaranteed Pass!!Current Update!!
Q1. What are normal organisms of the urinary tract (often contaminants from
other body sites)?
A: Staphylococcus epidermidis, Streptococcus spp., Corynebacterium
(diphtheroids), Escherichia coli, Lactobacillus spp., and yeast.
Q2. What are common sources of urinary tract contamination?
A: The urethra, vagina, perianal area, and skin.
Q3. Define a UTI.
A: Invasion of the urinary tract by microorganisms—usually bacteria ascending
from the urethra—affecting any urinary tract site.
(The body’s major defense is continuous urine flow and immune response.)
Q4. Match the infection type to its site of involvement:
A:
• Prostatitis → Prostate
• Pyelonephritis → Kidney
, • Ureteritis → Ureter
• Urethritis → Urethra
• Cystitis → Bladder
Q5. Outline the sequential steps in the pathogenesis of a UTI.
A:
1. Colonization of the urethra
2. Uroepithelium penetration in the bladder
3. Bacterial ascension through the ureters
4. Pyelonephritis, potentially leading to acute kidney injury
Q6. What are the common signs and symptoms of lower UTIs (bladder/urethra)?
A:
• Dysuria (painful or burning urination)
• Pyuria (WBCs >10/hpf or positive leukocyte esterase)
• Hemoglobinuria and proteinuria
Q7. Which populations are most at risk for UTIs?
A:
• Sexually active females
• Pregnant women
• Post-menopausal women
• Older males
• Infants
, • Catheterized patients
• Individuals with structural or physiological renal disease
Q8. Some antimicrobials have a narrow therapeutic index. What does this mean?
A: Their therapeutically effective concentrations are close to toxic levels.
Q9. Which drugs are known for a narrow therapeutic index and related toxicities?
A:
• Aminoglycosides, Vancomycin → Rise in creatinine & BUN (nephrotoxicity)
• Chloramphenicol, Linezolid → ↓ CBC and reticulocyte count (bone marrow
suppression)
Q10. What is the Schlichter Test used for?
A: A specialized broth dilution test (takes ~48 hours) used to assess if a
patient’s serum contains bactericidal concentrations of antibiotics after therapy.
Q11. What does the Schlichter Test determine?
A: Bactericidal activity of a patient’s serum against the infecting organism.
Q12. What does Cloxacillin inhibit?
A: AmpC β-lactamases.
Q13. What are AmpC β-lactamases and where are they found?
A: Enzymes isolated from Enterobacteriaceae and other Gram-negative
bacteria; confer resistance to 3rd generation cephalosporins, most penicillins, and
β-lactamase inhibitor combinations.
, Q14. What is the specialized screening test for ESBL production?
A: Inhibitor-potentiated disk diffusion test (confirmation testing).
Q15. Which routine MIC result pattern suggests ESBL production?
A: Increased resistance to 3rd-generation cephalosporins (e.g., cefotaxime,
ceftriaxone, ceftazidime, cefpodoxime) and aztreonam.
Q16. ESBLs are inhibited by what compound?
A: Clavulanic acid.
Q17. What antibiotic class is the treatment of choice for ESBL-producing bacteria
such as Klebsiella spp.?
A: Carbapenems.
Q18. What is the recommended disk concentration for specialized ESBL screening
using cefpodoxime?
A: 10 μg.
Q19. How should ESBL-positive isolates be reported, even if in vitro testing shows
susceptibility?
A: Report as resistant to penicillins, cephalosporins, and monobactams.
Q20. What is the Modified Hodge Test (MHT) used to detect?
A: Carbapenemase production in Enterobacteriaceae.
(Procedure: Lawn of carbapenem-susceptible E. coli is streaked on Mueller-Hinton
agar; test organism streaked from disk edge; incubate 16–24 hrs at 35°C.)
Q21. What does carbapenemase production allow?
A: Growth of carbapenem-susceptible E. coli around the test organism.
Q22. In which organism were carbapenemases initially identified and remain most
common?
A: Klebsiella pneumoniae.
Conceptual Actual Frequently Tested Exam
Questions With Reviewed 100% Correct
Detailed Answers
Guaranteed Pass!!Current Update!!
Q1. What are normal organisms of the urinary tract (often contaminants from
other body sites)?
A: Staphylococcus epidermidis, Streptococcus spp., Corynebacterium
(diphtheroids), Escherichia coli, Lactobacillus spp., and yeast.
Q2. What are common sources of urinary tract contamination?
A: The urethra, vagina, perianal area, and skin.
Q3. Define a UTI.
A: Invasion of the urinary tract by microorganisms—usually bacteria ascending
from the urethra—affecting any urinary tract site.
(The body’s major defense is continuous urine flow and immune response.)
Q4. Match the infection type to its site of involvement:
A:
• Prostatitis → Prostate
• Pyelonephritis → Kidney
, • Ureteritis → Ureter
• Urethritis → Urethra
• Cystitis → Bladder
Q5. Outline the sequential steps in the pathogenesis of a UTI.
A:
1. Colonization of the urethra
2. Uroepithelium penetration in the bladder
3. Bacterial ascension through the ureters
4. Pyelonephritis, potentially leading to acute kidney injury
Q6. What are the common signs and symptoms of lower UTIs (bladder/urethra)?
A:
• Dysuria (painful or burning urination)
• Pyuria (WBCs >10/hpf or positive leukocyte esterase)
• Hemoglobinuria and proteinuria
Q7. Which populations are most at risk for UTIs?
A:
• Sexually active females
• Pregnant women
• Post-menopausal women
• Older males
• Infants
, • Catheterized patients
• Individuals with structural or physiological renal disease
Q8. Some antimicrobials have a narrow therapeutic index. What does this mean?
A: Their therapeutically effective concentrations are close to toxic levels.
Q9. Which drugs are known for a narrow therapeutic index and related toxicities?
A:
• Aminoglycosides, Vancomycin → Rise in creatinine & BUN (nephrotoxicity)
• Chloramphenicol, Linezolid → ↓ CBC and reticulocyte count (bone marrow
suppression)
Q10. What is the Schlichter Test used for?
A: A specialized broth dilution test (takes ~48 hours) used to assess if a
patient’s serum contains bactericidal concentrations of antibiotics after therapy.
Q11. What does the Schlichter Test determine?
A: Bactericidal activity of a patient’s serum against the infecting organism.
Q12. What does Cloxacillin inhibit?
A: AmpC β-lactamases.
Q13. What are AmpC β-lactamases and where are they found?
A: Enzymes isolated from Enterobacteriaceae and other Gram-negative
bacteria; confer resistance to 3rd generation cephalosporins, most penicillins, and
β-lactamase inhibitor combinations.
, Q14. What is the specialized screening test for ESBL production?
A: Inhibitor-potentiated disk diffusion test (confirmation testing).
Q15. Which routine MIC result pattern suggests ESBL production?
A: Increased resistance to 3rd-generation cephalosporins (e.g., cefotaxime,
ceftriaxone, ceftazidime, cefpodoxime) and aztreonam.
Q16. ESBLs are inhibited by what compound?
A: Clavulanic acid.
Q17. What antibiotic class is the treatment of choice for ESBL-producing bacteria
such as Klebsiella spp.?
A: Carbapenems.
Q18. What is the recommended disk concentration for specialized ESBL screening
using cefpodoxime?
A: 10 μg.
Q19. How should ESBL-positive isolates be reported, even if in vitro testing shows
susceptibility?
A: Report as resistant to penicillins, cephalosporins, and monobactams.
Q20. What is the Modified Hodge Test (MHT) used to detect?
A: Carbapenemase production in Enterobacteriaceae.
(Procedure: Lawn of carbapenem-susceptible E. coli is streaked on Mueller-Hinton
agar; test organism streaked from disk edge; incubate 16–24 hrs at 35°C.)
Q21. What does carbapenemase production allow?
A: Growth of carbapenem-susceptible E. coli around the test organism.
Q22. In which organism were carbapenemases initially identified and remain most
common?
A: Klebsiella pneumoniae.
